FDA approves cooling cap for breast cancer hair loss
The U.S. Food and Drug Administration has approved the first ever cooling cap to help prevent hair loss among women undergoing breast cancer treatment. The Dignitana DigniCap Cooling System utilizes scalp cooling to minimize hair loss. Research found that up to 66% of women who used the cap experienced 50% or less hair loss.
Hair loss associated with breast cancer chemotherapy is a serious concern for many women, as hair loss can have devastating emotional and psychological effects. Recent studies have found that Taxotere, a drug commonly used in the breast cancer chemotherapy treatment regimen, could be associated with an increased risk of permanent hair loss.
Taxotere manufacturer Sanofi-Aventis allegedly knew about the risks of permanent hair loss associated with the drug, but failed to warn doctors or patients, according to recent Taxotere lawsuits filed against the company. According to some estimates, up to 75% of women who undergo chemotherapy for breast cancer received Taxotere as a part of their treatment.